Antibodies to Domain I β
antibodies to domain I β2 glycoprotein 1
antiphospholipid antibodies
antiphospholipid syndrome
pregnancy morbidity
thrombosis
Journal
Doklady. Biochemistry and biophysics
ISSN: 1608-3091
Titre abrégé: Dokl Biochem Biophys
Pays: United States
ID NLM: 101126895
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
27
03
2023
accepted:
19
04
2023
revised:
15
04
2023
medline:
23
10
2023
pubmed:
14
10
2023
entrez:
13
10
2023
Statut:
ppublish
Résumé
The role of antiphospholipid antibodies (aPL), which are not included in the Sydney diagnostic criteria, in antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) is poorly understood. The aim of this study was to determine the clinical significance of IgG antibodies for domain 1 of β
Identifiants
pubmed: 37833609
doi: 10.1134/S1607672923700278
pii: 10.1134/S1607672923700278
doi:
Substances chimiques
beta 2-Glycoprotein I
0
Antibodies, Anticardiolipin
0
Immunoglobulin G
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
219-226Informations de copyright
© 2023. Pleiades Publishing, Ltd.
Références
Ruiz-Irastorza, G., Crowther, M., Branch, W., and Khamashta, M.A., Antiphospholipid syndrome, Lancet, 2010, vol. 376, no. 9751, pp. 1498–1509.
pubmed: 20822807
doi: 10.1016/S0140-6736(10)60709-X
Antifosfolipidnyi sindrom (Antiphospholipid Syndrome), Nasonov, E.L., Ed., Moscow: Litterra, 2004.
Reshetnyak, T.M., Cheldieva, F.A., Nurbayeva, K.S., Lila, A.M., and Nasonov, E.L., Antiphospholipid syndrome: diagnosis, development, and therapy, Tromboz, Gemostaz Reologia, 2020, no. 4, pp. 4–21.
Reshetnyak, T.M., Antiphospholipid syndrome: diagnosis and clinical manifestations (a lecture), Nauchno-Prakt. Revmatol. 2014, vol. 52, no. 1, pp. 56–71.
Miyakis, S., Lockshin, M.D., Atsumi, T., et al., International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J. Thromb. Haemost., 2006, vol. 4, no. 2, pp. 295–306.
pubmed: 16420554
doi: 10.1111/j.1538-7836.2006.01753.x
Devreese, K.M.J., Ortel, T.L., Pengo, V., and de Laat, B., Subcommittee on lupus anticoagulant/antiphospholipid antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH, J. Thromb. Haemost., 2018, vol. 16, no. 4, pp. 809–813.
pubmed: 29532986
doi: 10.1111/jth.13976
Pengo, V., Ruffatti, A., Legnani, C., et al., Clinical course of high-risk patients diagnosed with antiphospholipid syndrome, J. Thromb. Haemost., 2010, vol. 8, no. 2, pp. 237–242.
pubmed: 19874470
doi: 10.1111/j.1538-7836.2009.03674.x
Vandevelde, A. and Devreese, K.M.J., Laboratory diagnosis of antiphospholipid syndrome: insights and hindrances, J. Clin. Med., 2022, vol. 11, no. 8, p. 2164.
pubmed: 35456258
pmcid: 9025581
doi: 10.3390/jcm11082164
Devreese, K.M.J., Zuily, S., and Meroni, P.L., Role of antiphospholipid antibodies in the diagnosis of antiphospholipid syndrome, J. Transl. Autoimmun., 2021, vol. 4, p. 100134.
pubmed: 34816113
pmcid: 8592860
doi: 10.1016/j.jtauto.2021.100134
de Laat, B., Derksen, R.H., Urbanus, R.T., and de Groot, P.G., IgG antibodies that recognize epitope Gly40–Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis, Blood, 2005, vol. 105, no. 4, pp. 1540–1545. https://doi.org/10.1182/blood-2004-09-3387
doi: 10.1182/blood-2004-09-3387
pubmed: 15507529
Yin, D., de Laat, B., Devreese, K.M.J., and Kelchtermans, H., The clinical value of assays detecting antibodies against domain I of β
pubmed: 30316989
doi: 10.1016/j.autrev.2018.06.011
De Craemer, A.S., Musial, J., and Devreese, K.M., Role of anti-domain 1-β
pubmed: 27314634
doi: 10.1111/jth.13389
Pengo, V., Ruffatti, A., Tonello, M., et al., Antiphospholipid syndrome: antibodies to domain 1 of beta2-glycoprotein 1 correctly classify patients at risk, J. Thromb. Haemost., 2015, vol. 13, no. 5, pp. 782–787.
pubmed: 25645395
doi: 10.1111/jth.12865
Yin, D., Chayoua, W., Kelchtermans, H., et al., Detection of anti-domain I antibodies by chemiluminescence enables the identification of high-risk antiphospholipid syndrome patients: a multicenter multiplatform study, J. Thromb. Haemost., 2020, vol. 18, no. 2, pp. 463–478.
pubmed: 31749277
doi: 10.1111/jth.14682
Nascimento, I.S., Radin, M., Gândara, A.P.R., Sciascia, S., and de Andrade, D.C.O., Global antiphospholipid syndrome score and anti-ß2-glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: a four-year prospective study, Lupus, 2020, vol. 29, no. 7, pp. 676–685.
pubmed: 32279584
doi: 10.1177/0961203320916527
Radin, M., Cecchi, I., Roccatello, D., et al., Prevalence and thrombotic risk assessment of Anti-β
pubmed: 28778105
doi: 10.1055/s-0037-1603936
Zuily, S., de Laat, B., Guillemin, F., et al., Anti-domain I β
pubmed: 32572467
doi: 10.1093/jalm/jfaa072
Chighizola, C.B., Pregnolato, F., Andreoli, L., et al., Beyond thrombosis: anti-β
pubmed: 29454510
doi: 10.1016/j.jaut.2018.02.002
Iwaniec, T., Kaczor, M.P., Celińska-Löwenhoff, M., et al., Clinical significance of anti-domain 1 β
pubmed: 28363116
doi: 10.1016/j.thromres.2017.02.019
Pignatelli, P., Ettorre, E., Menichelli, D., et al., Seronegative antiphospholipid syndrome: refining the value of “non-criteria” antibodies for diagnosis and clinical management, Haematologica, 2020, vol. 105, no. 3, pp. 562–572.
pubmed: 32001534
pmcid: 7049333
doi: 10.3324/haematol.2019.221945
Bradacova, P., Slavik, L., Ulehlova, J., et al., Current promising biomarkers and methods in the diagnostics of antiphospholipid syndrome: a review, Biomedicines, 2021, vol. 9, no. 2, p. 166.
pubmed: 33567576
pmcid: 7914732
doi: 10.3390/biomedicines9020166
Jiang, D., Lim, W., Crowther, M., and Garcia, D., A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations, Blood Adv., 2021, vol. 5, no. 20, pp. 3931–3936.
pubmed: 34547773
pmcid: 8945648
doi: 10.1182/bloodadvances.2021005205
Meroni, P.L., Borghi, M.O., Raschi, E., and Tedesco, F., Pathogenesis of antiphospholipid syndrome: understanding the antibodies, Nat. Rev. Rheumatol., 2011, vol. 7, no. 6, pp. 330–339.
pubmed: 21556027
doi: 10.1038/nrrheum.2011.52
Pal’keeva, M.E., Sidorova, M.V., Kuznetsova, T.V., Kobylyanskii, A.G., Tishchenko, V.A., Nasonov, E.L., et al., Synthesis and antigenic properties of peptide fragments of β
McDonnell, T., Wincup, C., Buchholz, I., et al., The role of beta-2-glycoprotein I in health and disease associating structure with function: more than just APS, Blood Rev., 2020, vol. 39, p. 100610.
pubmed: 31471128
pmcid: 7014586
doi: 10.1016/j.blre.2019.100610
Hochberg, M.C., Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus, Arthritis Rheum., 1997, vol. 40, no. 9, p. 1725.
pubmed: 9324032
doi: 10.1002/art.1780400928
Korneenkov, A.A., Ryazantsev, S.V., and Vyazems-kaya, E.E., Calculation and interpretation of indicators of informativeness of diagnostic medical technologies, Med. Council, 2019, no. 20, pp. 45–51.
Fletcher, R., Fletcher, S., and Wagner, E., Clinical Epidemiology. Fundamentals of Evidence-Based Medicine, Moscow: MediaSfera, 1998.
Weaver, J.C. and Krilis, S.A., Giannakopoulos B. Oxidative post-translational modification of beta 2-glycoprotein I in the pathophysiology of anti-phospholipid syndrome, Free Radical Biol. Med., 2018. https://doi.org/10.1016/j.freeradbiomed.2018.03.048
de Groot, P.G. and Meijers, J.C., β(2)-Glycoprotein I: evolution, structure and function, J. Thromb. Haemost., 2011, vol. 9, no. 7, pp. 1275–1284.
pubmed: 21535391
doi: 10.1111/j.1538-7836.2011.04327.x
de Laat, B., Derksen, R.H., van Lummel, M., et al., Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change, Blood, 2006, vol. 107, no. 5, pp. 1916–1924.
pubmed: 16269621
doi: 10.1182/blood-2005-05-1943
Iverson, G.M., Victoria, E.J., and Marquis, D.M., Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI, Proc. Natl. Acad. Sci. U. S. A., 1998, vol. 95, no. 26, pp. 15542–15546.
pubmed: 9861005
pmcid: 28079
doi: 10.1073/pnas.95.26.15542
Mahler, M., Norman, G.L., Meroni, P.L., and Khamashta, M., Autoantibodies to domain 1 of beta 2 glycoprotein 1: a promising candidate biomarker for risk management in antiphospholipid syndrome, Autoimmun. Rev., 2012, vol. 12, no. 2, pp. 313–317.
pubmed: 22652408
doi: 10.1016/j.autrev.2012.05.006
Chighizola, C.B., Gerosa, M., and Meroni, P.L., New tests to detect antiphospholipid antibodies: anti-domain I beta-2-glycoprotein-I antibodies, Curr. Rheumatol. Rep., 2014, vol. 16, no. 2, p. 402.
pubmed: 24390756
doi: 10.1007/s11926-013-0402-7
Ioannou, Y., Romay-Penabad, Z., Pericleous, C., et al., In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept, J. Thromb. Haemost., 2009, vol. 7, no. 5, pp. 833–842.
pubmed: 19220729
doi: 10.1111/j.1538-7836.2009.03316.x
Pericleous, C., Ruiz-Limón, P., Romay-Penabad, Z., Marín, A.C., et al., Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β
pubmed: 25273993
doi: 10.1093/rheumatology/keu360
de Laat, B., Derksen, R.H., Urbanus, R.T., and de Groot, P.G., IgG antibodies that recognize epitope Gly40–Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis, Blood, 2005, vol. 105, no. 4, pp. 1540–1545.
pubmed: 15507529
doi: 10.1182/blood-2004-09-3387
Colasanti, T., Alessandri, C., Capozzi, A., et al., Autoantibodies specific to a peptide of β
pubmed: 22932793
doi: 10.1182/blood-2011-09-378851
Mondejar, R., González-Rodríguez, C., Toyos-Sáenz de Miera, F.J., et al., Role of antiphospholipid score and anti-β
pubmed: 24522162
doi: 10.1016/j.cca.2014.01.047
Zhang, S., Wu, Z., Li, P., et al., Evaluation of the clinical performance of a novel chemiluminescent immunoassay for detection of anticardiolipin and anti-beta2-glycoprotein 1 antibodies in the diagnosis of antiphospholipid syndrome, Medicine (Baltimore), 2015, vol. 94, no. 46, p. e2059.
pubmed: 26579816
pmcid: 4652825
doi: 10.1097/MD.0000000000002059
Zhang, S., Wu, Z., Chen, S., et al., Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome, Sci. Rep., 2016, vol. 6, p. 23839.
pubmed: 27053361
pmcid: 4823723
doi: 10.1038/srep23839
Rodríguez-García, V., Ioannou, Y., Fernández-Nebro, A., et al., Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review, Rheumatology (Oxford), 2015, vol. 54, no. 11, pp. 2042–2050.
pubmed: 26152548
doi: 10.1093/rheumatology/kev226
Tonello, M., Mattia, E., Del Ross, T., et al., Clinical value of anti-domain I-β
pubmed: 29953850
doi: 10.1016/j.cca.2018.06.037
Liu, T., Gu, J., Wan, L., et al., Anti-β
pubmed: 31816554
doi: 10.1016/j.thromres.2019.11.029
Liu, T., Gu, J., Wan, L., et al., “Non-criteria” antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort, Arthritis Res. Ther., 2020, vol. 22, no. 1, p. 33.
pubmed: 32085759
pmcid: 7035660
doi: 10.1186/s13075-020-2131-4
Pengo, V., Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome, J. Thromb. Haemost., 2020, vol. 18, no. 8, pp. 1846–1848.
pubmed: 32428999
doi: 10.1111/jth.14896